Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1993 Jun 5;306(6891):1514–1518. doi: 10.1136/bmj.306.6891.1514

Association between availability of non-prescription beta 2 agonist inhalers and undertreatment of asthma.

P Gibson 1, D Henry 1, L Francis 1, D Cruickshank 1, F Dupen 1, N Higginbotham 1, R Henry 1, D Sutherland 1
PMCID: PMC1677936  PMID: 8518681

Abstract

OBJECTIVE--To determine whether the availability of beta 2 agonist inhalers without prescription leads to undertreatment of asthma. DESIGN--Cross sectional study of adequacy of treatment in asthmatic subjects who purchased beta 2 agonist inhalers and subjects who obtained inhalers by prescription. SETTING--Community pharmacies in New South Wales, Australia. SUBJECTS--403 eligible consecutive asthmatic subjects aged 13 to 55 purchasing salbutamol metered dose inhalers over the counter or by prescription; 197 attended for follow up and spirometry and 139 returned 14 day symptom, peak flow, and medication diaries. MAIN OUTCOME MEASURES--Severity of asthma assessed on frequency of day time and night time wheezing, frequency of inhaler use, and peak expiratory flow rates. Adequacy of treatment according to published guidelines. RESULTS--Of the 139 patients who completed the diary 83, (60%) purchased their inhalers without prescription and 83 were undertreated. The characteristics of patients in the prescription and purchasing groups were similar. Multiple logistic regression analysis identified use of non-prescribed salbutamol as being associated with a 2.9-fold increase in the odds of undertreatment (95% confidence interval 1.3 to 6.8). Smoking increased the odds of undertreatment (3.3, 1.2 to 9.5) and use of a peak flow meter reduced the odds (0.11, 0.04 to 0.34). Adjustment for frequency of consultation made use of non-prescription salbutamol insignificant (1.4, 0.55 to 3.8). Attitudes to services provided by doctors and pharmacists were favourable and not associated with undertreatment. CONCLUSION--Over the counter purchase of salbutamol is associated with infrequent consultation with doctors and undertreatment of asthma.

Full text

PDF
1514

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauman A., Young L., Peat J. K., Hunt J., Larkin P. Asthma under-recognition and under-treatment in an Australian community. Aust N Z J Med. 1992 Feb;22(1):36–40. doi: 10.1111/j.1445-5994.1992.tb01706.x. [DOI] [PubMed] [Google Scholar]
  2. Cranz H. Over-the-counter drugs. The issues. Drug Saf. 1990;5 (Suppl 1):120–125. doi: 10.2165/00002018-199000051-00019. [DOI] [PubMed] [Google Scholar]
  3. Fennerty A. G., Banks J., Ebden P., Bevan C. The effect of cigarette withdrawal on asthmatics who smoke. Eur J Respir Dis. 1987 Nov;71(5):395–399. [PubMed] [Google Scholar]
  4. Fitzclarence C. A., Henry R. L. Validation of an asthma knowledge questionnaire. J Paediatr Child Health. 1990 Aug;26(4):200–204. doi: 10.1111/j.1440-1754.1990.tb02429.x. [DOI] [PubMed] [Google Scholar]
  5. Hargreave F. E., Dolovich J., Newhouse M. T. The assessment and treatment of asthma: a conference report. J Allergy Clin Immunol. 1990 Jun;85(6):1098–1111. doi: 10.1016/0091-6749(90)90056-a. [DOI] [PubMed] [Google Scholar]
  6. Hendeles L., Weinberger M. Nonprescription sale of inhaled metaproterenol--déjà vu. N Engl J Med. 1984 Jan 19;310(3):207–208. doi: 10.1056/NEJM198401193100326. [DOI] [PubMed] [Google Scholar]
  7. Henry D. A., Sutherland D., Francis L. The use of non-prescription salbutamol inhalers by asthmatic patients in the Hunter Valley, New South Wales. Newcastle Retail Pharmacy Research Group. Med J Aust. 1989 Apr 17;150(8):445–449. [PubMed] [Google Scholar]
  8. Jenkins M. A., Hurley S. F., Bowes G., McNeil J. J. Use of antiasthmatic drugs in Australia. Med J Aust. 1990 Sep 17;153(6):323–328. doi: 10.5694/j.1326-5377.1990.tb136939.x. [DOI] [PubMed] [Google Scholar]
  9. Johnson A. J., Nunn A. J., Somner A. R., Stableforth D. E., Stewart C. J. Circumstances of death from asthma. Br Med J (Clin Res Ed) 1984 Jun 23;288(6434):1870–1872. doi: 10.1136/bmj.288.6434.1870. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Knight A., Breslin A. B. Passive cigarette smoking and patients with asthma. Med J Aust. 1985 Feb 4;142(3):194–195. doi: 10.5694/j.1326-5377.1985.tb133098.x. [DOI] [PubMed] [Google Scholar]
  11. Madhavan S., Schondelmeyer S. W. Pharmacists' evaluations of the nonprescription availability of metaproterenol, cimetidine, ibuprofen, and nystatin. Am J Hosp Pharm. 1989 Dec;46(12):2486–2492. [PubMed] [Google Scholar]
  12. McLeod D. C. Nonprescription drug approval: therapeutic strategy or marketing decision? DICP. 1989 Jul-Aug;23(7-8):606–609. doi: 10.1177/1060028089023007-820. [DOI] [PubMed] [Google Scholar]
  13. Rea H. H., Scragg R., Jackson R., Beaglehole R., Fenwick J., Sutherland D. C. A case-control study of deaths from asthma. Thorax. 1986 Nov;41(11):833–839. doi: 10.1136/thx.41.11.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  15. Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
  16. Woolcock A., Rubinfeld A. R., Seale J. P., Landau L. L., Antic R., Mitchell C., Rea H. H., Zimmerman P. Thoracic society of Australia and New Zealand. Asthma management plan, 1989. Med J Aust. 1989 Dec 4;151(11-12):650–653. [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES